Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer.


Journal

Angiogenesis
ISSN: 1573-7209
Titre abrégé: Angiogenesis
Pays: Germany
ID NLM: 9814575

Informations de publication

Date de publication:
05 2020
Historique:
received: 10 07 2019
accepted: 09 10 2019
revised: 26 09 2019
pubmed: 2 11 2019
medline: 14 1 2021
entrez: 1 11 2019
Statut: ppublish

Résumé

WNT2 acts as a pro-angiogenic factor in placental vascularization and increases angiogenesis in liver sinusoidal endothelial cells (ECs) and other ECs. Increased WNT2 expression is detectable in many carcinomas and participates in tumor progression. In human colorectal cancer (CRC), WNT2 is selectively elevated in cancer-associated fibroblasts (CAFs), leading to increased invasion and metastasis. However, if there is a role for WNT2 in colon cancer, angiogenesis was not addressed so far. We demonstrate that WNT2 enhances EC migration/invasion, while it induces canonical WNT signaling in a small subset of cells. Knockdown of WNT2 in CAFs significantly reduced angiogenesis in a physiologically relevant assay, which allows precise assessment of key angiogenic properties. In line with these results, expression of WNT2 in otherwise WNT2-devoid skin fibroblasts led to increased angiogenesis. In CRC xenografts, WNT2 overexpression resulted in enhanced vessel density and tumor volume. Moreover, WNT2 expression correlates with vessel markers in human CRC. Secretome profiling of CAFs by mass spectrometry and cytokine arrays revealed that proteins associated with pro-angiogenic functions are elevated by WNT2. These included extracellular matrix molecules, ANG-2, IL-6, G-CSF, and PGF. The latter three increased angiogenesis. Thus, stromal-derived WNT2 elevates angiogenesis in CRC by shifting the balance towards pro-angiogenic signals.

Identifiants

pubmed: 31667643
doi: 10.1007/s10456-019-09688-8
pii: 10.1007/s10456-019-09688-8
pmc: PMC7160098
doi:

Substances chimiques

Culture Media, Conditioned 0
WNT2 protein, human 0
Wnt2 Protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

159-177

Subventions

Organisme : Austrian Science Fund
ID : P29222-B28
Pays : International
Organisme : Austrian Science Fund
ID : SFB F4707 and SFB-F06105
Pays : International

Références

Clin Proteomics. 2017 Oct 6;14:33
pubmed: 29176937
Genes Dev. 2005 Apr 15;19(8):877-90
pubmed: 15833914
Nature. 2010 Nov 11;468(7321):310-5
pubmed: 21068842
Front Biosci. 2008 May 01;13:6537-53
pubmed: 18508679
Mol Cell Biol. 2007 Nov;27(21):7551-9
pubmed: 17785439
Oncol Lett. 2018 Sep;16(3):2857-2864
pubmed: 30127872
Annu Rev Pathol. 2006;1:119-50
pubmed: 18039110
Int J Oncol. 2001 Nov;19(5):1003-7
pubmed: 11605001
Am J Cancer Res. 2014 Sep 06;4(5):537-44
pubmed: 25232495
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Front Biosci (Landmark Ed). 2010 Jan 01;15:166-79
pubmed: 20036813
Cancer Metastasis Rev. 2007 Dec;26(3-4):489-502
pubmed: 17717633
Cardiovasc Res. 2010 May 1;86(2):226-35
pubmed: 20154066
Cold Spring Harb Perspect Med. 2012 Dec 01;2(12):a006676
pubmed: 23209177
J Proteome Res. 2014 Dec 5;13(12):5989-6000
pubmed: 25347463
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Genes Dev. 2016 May 1;30(9):1002-19
pubmed: 27151975
Nat Protoc. 2010 Jun;5(6):1081-95
pubmed: 20539284
Oncogene. 2017 Sep 28;36(39):5460-5472
pubmed: 28553956
Cold Spring Harb Perspect Biol. 2011 Dec 01;3(12):
pubmed: 21917992
Nat Genet. 2015 Apr;47(4):320-9
pubmed: 25706628
Angiogenesis. 2009;12(3):251-65
pubmed: 19444628
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Cancer Cell. 2004 Nov;6(5):507-16
pubmed: 15542434
Int J Mol Sci. 2017 Dec 13;18(12):
pubmed: 29236046
BMC Cancer. 2013 Jul 01;13:316
pubmed: 23815780
Cell Cycle. 2008 Jul 1;7(13):2056-70
pubmed: 18642446
FASEB J. 1997 Jan;11(1):51-9
pubmed: 9034166
J Mol Cell Cardiol. 2012 Mar;52(3):650-9
pubmed: 22146296
Semin Cancer Biol. 2009 Oct;19(5):329-37
pubmed: 19482086
Int J Mol Sci. 2012;13(8):9545-71
pubmed: 22949815
PLoS One. 2016 Aug 11;11(8):e0160414
pubmed: 27513465
Proteomics. 2013 Jan;13(2):379-88
pubmed: 23175172
Cancer Metastasis Rev. 2012 Jun;31(1-2):195-208
pubmed: 22101652
Oncogene. 2015 Feb 12;34(7):815-25
pubmed: 24632618
BMC Cancer. 2014 Dec 17;14:970
pubmed: 25518851
Nat Commun. 2018 Mar 19;9(1):1132
pubmed: 29556067
Development. 1996 Nov;122(11):3343-53
pubmed: 8951051
PLoS One. 2010 Feb 23;5(2):e9370
pubmed: 20186325
Cardiovasc Res. 2008 May 1;78(2):203-12
pubmed: 18079100
Genes Dev. 2003 Jul 15;17(14):1709-13
pubmed: 12865297
Lab Invest. 1997 Apr;76(4):517-31
pubmed: 9111514
Dev Biol. 2011 Aug 15;356(2):541-52
pubmed: 21704027
PLoS One. 2019 Feb 22;14(2):e0212711
pubmed: 30794657
Nat Commun. 2015 Jan 05;6:5846
pubmed: 25556612
Br J Cancer. 2014 Jan 21;110(2):469-78
pubmed: 24346288
Arterioscler Thromb Vasc Biol. 2016 Jul;36(7):1417-24
pubmed: 27199447
PLoS One. 2013 Sep 16;8(9):e74250
pubmed: 24066126
J Natl Cancer Inst. 1982 Sep;69(3):699-708
pubmed: 6180212
Nat Genet. 2015 Apr;47(4):312-9
pubmed: 25706627
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
Mol Cell Proteomics. 2018 Feb;17(2):290-303
pubmed: 29196338
Oncogene. 1996 Jan 4;12(1):153-8
pubmed: 8552386
Biochem Biophys Res Commun. 2002 Oct 4;297(4):1058-61
pubmed: 12359263
Nat Methods. 2010 Sep;7(9):681-5
pubmed: 20805795
J Vis Exp. 2007;(3):186
pubmed: 18978935
Int J Mol Sci. 2016 Nov 01;17(11):
pubmed: 27809279
APMIS. 2003 Jun;111(6):658-68
pubmed: 12969022
Cancer Cell. 2002 Feb;1(1):99-108
pubmed: 12086892
Growth Factors. 2007 Feb;25(1):25-32
pubmed: 17454147
SLAS Discov. 2017 Jun;22(5):602-613
pubmed: 28346097
J Thromb Haemost. 2010 Jul;8(7):1614-23
pubmed: 20456757
J Transl Med. 2013 May 03;11:110
pubmed: 23639003
Gut. 2011 Dec;60(12):1635-43
pubmed: 21672941
Clin Cancer Res. 2013 Nov 1;19(21):6006-19
pubmed: 24025712
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
PLoS One. 2011;6(11):e27385
pubmed: 22110636
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Biomed Res Int. 2014;2014:756078
pubmed: 24949467
Nat Rev Cancer. 2003 Jun;3(6):401-10
pubmed: 12778130
Hepatology. 2008 Mar;47(3):1018-31
pubmed: 18302287
Dev Biol. 2010 May 1;341(1):126-40
pubmed: 19854168

Auteurs

Daniela Unterleuthner (D)

Institute of Medical Genetics, Medical University of Vienna, Währinger Straße 10, 1090, Vienna, Austria.

Patrick Neuhold (P)

Institute of Medical Genetics, Medical University of Vienna, Währinger Straße 10, 1090, Vienna, Austria.

Katharina Schwarz (K)

Institute of Medical Genetics, Medical University of Vienna, Währinger Straße 10, 1090, Vienna, Austria.

Lukas Janker (L)

Institute of Analytical Chemistry, University of Vienna, Währinger Straße 38, 1090, Vienna, Austria.

Benjamin Neuditschko (B)

Institute of Analytical Chemistry, University of Vienna, Währinger Straße 38, 1090, Vienna, Austria.

Harini Nivarthi (H)

Ludwig Boltzmann Institute for Cancer Research, Währinger Straße 13a, 1090, Vienna, Austria.
CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 14, 1090, Vienna, Austria.

Ilija Crncec (I)

Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8, 1090, Vienna, Austria.
Servier Pharma, Tuškanova 37, 10 000, Zagreb, Croatia.

Nina Kramer (N)

Institute of Medical Genetics, Medical University of Vienna, Währinger Straße 10, 1090, Vienna, Austria.
Department for Companion Animals and Horses, University of Veterinary Medicine, Veterinärplatz 1, 1210, Vienna, Austria.

Christine Unger (C)

Institute of Medical Genetics, Medical University of Vienna, Währinger Straße 10, 1090, Vienna, Austria.

Markus Hengstschläger (M)

Institute of Medical Genetics, Medical University of Vienna, Währinger Straße 10, 1090, Vienna, Austria.

Robert Eferl (R)

Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8, 1090, Vienna, Austria.

Richard Moriggl (R)

Ludwig Boltzmann Institute for Cancer Research, Währinger Straße 13a, 1090, Vienna, Austria.
Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Veterinärplatz 1, 1210, Vienna, Austria.

Wolfgang Sommergruber (W)

Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, 1130, Vienna, Austria.
Biotechnology, University of Applied Sciences, FH Campus Wien, Helmut- Qualtinger-Gasse 2, 1030, Vienna, Austria.

Christopher Gerner (C)

Institute of Analytical Chemistry, University of Vienna, Währinger Straße 38, 1090, Vienna, Austria.

Helmut Dolznig (H)

Institute of Medical Genetics, Medical University of Vienna, Währinger Straße 10, 1090, Vienna, Austria. helmut.dolznig@meduniwien.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH